Fresh Twist: India Stays Revocation Order On Novartis Ceritinib Patent
Executive Summary
Appellate board stays previous order that rescinded the patent on ceritinib in India, giving Novartis the upper hand for now. The spotlight is now on procedural aspects and additional evidence/submission by challenger Natco and rebuttal by the Swiss multinational.